Table 1.
Characteristics of the patients
| Parameter | (n = 51) subgroup (%) | 2-years DFS (%) | RR | p-value |
|---|---|---|---|---|
| Gender | ||||
| Male | 25 (49) | 78 | 1.06 | 0.91 |
| Female | 26 (51) | 75 | ||
| Age [median (range)] (years) | 65 (34–79) | |||
| <63 | 25 (49) | 78 | 1.01 | 0.85 |
| ≥63 | 26 (51) | 62 | ||
| Zubrod index | ||||
| 0 | 37 (72) | 88 | 1.9 | 0.06 |
| 1 | 14 (28) | 58 | ||
| c Tumour stage | ||||
| c T2 | 0 | – | – | – |
| c T3 | 51 (100) | 76 | ||
| c Nodal stage | ||||
| c N0 | 16 (32) | 80 | 1.17 | 0.68 |
| c N1 | 23 (45) | 77 | ||
| c N2 | 12 (23) | 73 | ||
| Number of cycles of 5Fu during radiotherapy | ||||
| 1 | 24 (45) | 81 | 1.56 | 0.46 |
| 2 | 27 (55) | 73 | ||
| yp Tumour stage | ||||
| ypT0 | 8 (15) | 100 | 5.15 | 0.001a |
| ypT1 | 3 (6) | 100 | ||
| ypT2 | 12 (24) | 91 | ||
| ypT3 | 28 (55) | 65 | ||
| yp Nodal stage | ||||
| yp N0 | 29 (57) | 89 | 2.77 | 0.007a |
| yp N1 | 14 (27) | 61 | ||
| yp N2 | 8 (16) | 40 | ||
| TRG scale | ||||
| 0 | 8 (15) | 100 | 2.63 | 0.004a |
| 1 | 20 (40) | 89 | ||
| 2 | 18 (35) | 55 | ||
| 3 | 5 (10) | 60 | ||
| Post-operative chemotherapy | ||||
| No | 31 (61) | 100 | 4.04 | 0.0008a |
| Yes | 20 (39) | 58 | ||
| CEA before treatment | ||||
| ≤5 ng ml−1 | 29 (57%) | 93 | 4.93 | 0.006a |
| >5 ng ml−1 | 17 (33%) | 49 | ||
| Missing | 5 (10%) | – | ||
5FU, 5-fluorouracil; CEA, carcinoembryonic antigen; DFS, disease-free survival; RR, Relative Risk; TRG, tumour regression grade.
a
p < 0.05.